Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR5 | P51681 | 1/20 | 0.54 |
| ▸ | MAOB | P27338 | 4/20 | 0.51 |
| ▸ | MAOA | P21397 | 2/20 | 0.51 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.48 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.47 |
| ▸ | IGF1R | P08069 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.45 |
| ▸ | APP | P05067 | 3/20 | 0.45 |
| ▸ | PTGER1 | P34995 | 2/20 | 0.45 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.44 |
| ▸ | NOS2 | P35228 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29858839 | 0.88 | CCR5 (0.57) | CCR5MAOBMAOALRRK2HDAC8 | |
| SCHEMBL18397358 | 0.88 | CCR5 (0.57) | CCR5MAOBMAOALRRK2HDAC8 | |
| SCHEMBL25180595 | 0.86 | CCR5 (0.57) | CCR5MAOBLRRK2APPPTGER1 | |
| SCHEMBL30682049 | 0.84 | CCR5 (0.56) | CCR5MAOBLRRK2APPPTGER1 | |
| SCHEMBL1549790 | 0.83 | MAOB (0.53) | CCR5MAOBLRRK2APPPTGER1 | |
| SCHEMBL190649 | 0.82 | MAOB (0.51) | CCR5MAOBLRRK2APPNPC1 | |
| SCHEMBL28921334 | 0.82 | MAOB (0.51) | MAOBMAOAIGF1RALOX15APP | |
| SCHEMBL3931258 | 0.81 | CCR5 (0.56) | CCR5MAOBLRRK2APPPTGER1 | |
| SCHEMBL7975050 | 0.81 | MAOB (0.65) | MAOBMAOANPC1RAB9A | |
| SCHEMBL30133911 | 0.81 | MAOB (0.63) | CCR5MAOBMAOALRRK2HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119119033-A | Pyrazolopyridone compounds | 百济神州有限公司 | 2024-12-13 | — | — | CN | disclosed |
| US-20240300951-A1 | Pyrazolopyridinone Compounds | BEIGENE LTD. (KY) | 2024-09-12 | — | — | US | disclosed |
| US-20240270751-A1 | Pyrazolopyridinone Compounds | BEIGENE LTD. (KY) | 2024-08-15 | — | — | US | disclosed |
| EP-4380936-A1 | PYRAZOLOPYRIDINONE COMPOUNDS | BeiGene, Ltd. (KY) | 2024-06-12 | — | — | EP | disclosed |
| CN-117836296-A | Pyrazolopyridone compounds | 百济神州有限公司 | 2024-04-05 | — | — | CN | disclosed |
| WO-2023011456-A1 | PYRAZOLOPYRIDINONE COMPOUNDS | BEIGENE, LTD. (KY) | 2023-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240300951-A1 | Pyrazolopyridinone Compounds | NFATC1, CD4, PBK | CCR5 36/4885MAOB 4197/4885MAOA 4149/4885 |
| US-20240270751-A1 | Pyrazolopyridinone Compounds | NFATC1, CD4, PBK | CCR5 36/4885MAOB 4197/4885MAOA 4149/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.